Spots Global Cancer Trial Database for advanced hepatocellular carcinoma (hcc)
Every month we try and update this database with for advanced hepatocellular carcinoma (hcc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC | NCT04523493 | Advanced Hepato... | Toripalimab com... Placebo combine... | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC) | NCT04605796 | Advanced Hepato... | Toripalimab com... | 18 Years - 70 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. | NCT01035229 | Carcinoma | Everolimus Everolimus Plac... Best Supportive... | 18 Years - | Novartis | |
| A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC) | NCT05375604 | Advanced Hepato... Gastric Cancer ... Colorectal Canc... | CDK-004 | 18 Years - | Codiak BioSciences | |
| Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC | NCT04723004 | Advanced Hepato... | Toripalimab com... Sorafenib | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients | NCT04212221 | Advanced Hepato... | MGD013 monother... MGD013 in combi... | 18 Years - 75 Years | Zai Lab (Hong Kong), Ltd. | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. | NCT01035229 | Carcinoma | Everolimus Everolimus Plac... Best Supportive... | 18 Years - | Novartis | |
| Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC) | NCT02906397 | ADVANCED HEPATO... | Galunisertib 15... Stereotactic Bo... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma | NCT05862181 | Advanced Hepato... | DEB-TACE plus H... | 18 Years - | Peking University Cancer Hospital & Institute | |
| The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC | NCT02814461 | Advanced Hepato... | Axitinib Radiation | 20 Years - 85 Years | Shin Kong Wu Ho-Su Memorial Hospital | |
| Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC | NCT04723004 | Advanced Hepato... | Toripalimab com... Sorafenib | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC) | NCT05375604 | Advanced Hepato... Gastric Cancer ... Colorectal Canc... | CDK-004 | 18 Years - | Codiak BioSciences | |
| A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC | NCT01101906 | Advanced Hepato... | OSI-906 Placebo | 18 Years - | Astellas Pharma Inc | |
| The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC | NCT02814461 | Advanced Hepato... | Axitinib Radiation | 20 Years - 85 Years | Shin Kong Wu Ho-Su Memorial Hospital | |
| A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC | NCT01101906 | Advanced Hepato... | OSI-906 Placebo | 18 Years - | Astellas Pharma Inc | |
| A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) | NCT04344158 | Advanced Hepato... | AK105 Injection Anlotinib Hydro... Sorafenib Tosyl... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) | NCT04985136 | Advanced Hepato... | camrelizumab；Ri... Rivoceranib Sorafenib Regorafenib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) | NCT04344158 | Advanced Hepato... | AK105 Injection Anlotinib Hydro... Sorafenib Tosyl... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma | NCT05862181 | Advanced Hepato... | DEB-TACE plus H... | 18 Years - | Peking University Cancer Hospital & Institute | |
| A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC) | NCT04605796 | Advanced Hepato... | Toripalimab com... | 18 Years - 70 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) | NCT04985136 | Advanced Hepato... | camrelizumab；Ri... Rivoceranib Sorafenib Regorafenib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
